Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized study of telisotuzumab vedotin versus docetaxel in previously treated c-Met overexpressing EGFR wild-type non-squamous NSCLC
MOH_2022-03-27_010560Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Telisotuzumab vedotin with Docetaxel (2 arms). Started Nov 2021; status: recruiting.
02
Drugs
telisotuzumab vedotindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-03-27_010560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-27_010560.